L
Laviana Pharma
Specializes in providing process and manufacture outsourcing services for the pharmaceutical industry
About Laviana Pharma
Established in 2003, Laviana Pharma is a contract development and manufacturing organization (CDMO) that provides integrated outsourcing services to the pharmaceutical and biopharmaceutical sectors. The company's business model is centered on offering comprehensive chemistry, manufacturing, and controls (CMC) services for small-molecule drugs, covering the entire lifecycle from preclinical laboratory research to commercialization. Laviana Pharma generates revenue by providing these specialized services to a global clientele, including companies in North America, Europe, and East Asia.
The company was co-founded by Chen Wenting, who serves as the board chairman. Mr. Chen graduated from Tsinghua University and New Mexico State University and brought over three decades of R&D and process experience to the firm. Before establishing Laviana, he held positions in the R&D departments of major pharmaceutical companies like Bristol-Myers Squibb, DuPont-Merck, and SmithKline Beecham. His background includes extensive work in medicinal chemistry and synthetic chemical process research, and he is a lead inventor on fifteen international patents for innovative drugs.
Laviana Pharma offers a suite of services that includes custom synthesis, process research and development (R&D), scale-up synthesis, and contract manufacturing of active pharmaceutical ingredients (API) and intermediates. The firm supports the development of innovative drugs through pilot-scale manufacturing, commercialization, and assistance with regulatory submissions for investigational new drugs (IND) and new drug applications (NDA). A key aspect of their offering is the focus on process development and optimization, aiming to bridge the gap between laboratory-scale synthesis and industrial production. The company also provides services for solid oral formulations like tablets and capsules, analytical development, and quality control studies.
Significant milestones for Laviana Pharma include completing its first round of financing in 2015 and listing on the NEEQ in 2016. The company has secured multiple rounds of financing, including Series C and C+ rounds, to fuel its expansion. It operates an R&D center in Tianjin, a GMP production campus in Cangzhou, and a commercial-scale production facility in Jiangsu, alongside business centers in Beijing, Shanghai, and several international sites. The company has received numerous accolades, such as being named one of the "Top 10 Most Growing CXO Companies" and obtaining CNAS certification for its testing center.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 24.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Outsourcing, Biotechnology, Pharmaceutical, Techbio, biomanufacturing, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Dec 2022 | $28M | $110M | Lujiang City Investment | ↗ |
| SERIES COther financing | Oct 2021 | $69M | $275M | Yingke Capital | ↗ |
Growth signals
Latest recorded traffic for Laviana Pharma is 200 monthly website visits, up 42.9% over the last three months. Laviana Pharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Laviana Pharma in its local ecosystem
The Laviana Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- HCHY Capital
ABC Capital
LYFE Capital
Series B and later2 investors entered at this stage
Yingke Capital- LILujiang City Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Laviana Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Laviana Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







